The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 ...

Ozempic, and the class of weight loss drugs it has come to embody, has left its imprint seemingly everywhere: On the lives of ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

And then there is the dividend. Coca-Cola is a Dividend King, or a corporation that has increased its payouts for at least 50 consecutive years. Coca-Cola's streak stands at 63 right now, making it an ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

"America's Next Top Model" winner India Gants reveals how she lost 50 pounds without dieting by quitting alcohol, eating ...

A weight loss drug dubbed the "triple G" drug for its effectiveness in mimicking three hunger-regulating hormones showed ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...